JP7432506B2 - 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤 - Google Patents

脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤 Download PDF

Info

Publication number
JP7432506B2
JP7432506B2 JP2020523790A JP2020523790A JP7432506B2 JP 7432506 B2 JP7432506 B2 JP 7432506B2 JP 2020523790 A JP2020523790 A JP 2020523790A JP 2020523790 A JP2020523790 A JP 2020523790A JP 7432506 B2 JP7432506 B2 JP 7432506B2
Authority
JP
Japan
Prior art keywords
virus
surfactant
item
compound
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020523790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501163A5 (enExample
JP2021501163A (ja
Inventor
ジャン－バティスト ファルセット，
ヨハンナ キンデルマン，
ビイエルン チッレ，
トーマス エル． クライル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2021501163A publication Critical patent/JP2021501163A/ja
Publication of JP2021501163A5 publication Critical patent/JP2021501163A5/ja
Application granted granted Critical
Publication of JP7432506B2 publication Critical patent/JP7432506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/37—Polymers
    • C11D3/3703—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C11D3/3707—Polyethers, e.g. polyalkyleneoxides
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
    • C11D1/66—Non-ionic compounds
    • C11D1/72—Ethers of polyoxyalkylene glycols
    • C11D1/721—End blocked ethers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2612—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aromatic or arylaliphatic hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G59/00—Polycondensates containing more than one epoxy group per molecule; Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups
    • C08G59/14—Polycondensates modified by chemical after-treatment
    • C08G59/1433—Polycondensates modified by chemical after-treatment with organic low-molecular-weight compounds
    • C08G59/1438—Polycondensates modified by chemical after-treatment with organic low-molecular-weight compounds containing oxygen
    • C08G59/1444—Monoalcohols
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3344—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing oxygen in addition to sulfur
    • C08G65/3346—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing oxygen in addition to sulfur having sulfur bound to carbon and oxygen
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/36—Organic compounds containing phosphorus
    • C11D3/362—Phosphates or phosphites
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/43—Solvents
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24361—Methods of inactivation or attenuation
    • C12N2770/24363—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polyethers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Detergent Compositions (AREA)
JP2020523790A 2017-10-30 2018-10-30 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤 Active JP7432506B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762578648P 2017-10-30 2017-10-30
US62/578,648 2017-10-30
US201862687023P 2018-06-19 2018-06-19
US62/687,023 2018-06-19
PCT/EP2018/079721 WO2019086463A1 (en) 2017-10-30 2018-10-30 Environmentally compatible detergents for inactivation of lipid-enveloped viruses

Publications (3)

Publication Number Publication Date
JP2021501163A JP2021501163A (ja) 2021-01-14
JP2021501163A5 JP2021501163A5 (enExample) 2021-12-16
JP7432506B2 true JP7432506B2 (ja) 2024-02-16

Family

ID=64083092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020523790A Active JP7432506B2 (ja) 2017-10-30 2018-10-30 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤

Country Status (12)

Country Link
US (1) US12258540B2 (enExample)
EP (1) EP3704178B1 (enExample)
JP (1) JP7432506B2 (enExample)
KR (1) KR102651043B1 (enExample)
CN (1) CN111511800B (enExample)
AU (1) AU2018357917B2 (enExample)
CA (1) CA3080656A1 (enExample)
CO (1) CO2020006181A2 (enExample)
ES (1) ES2991988T3 (enExample)
MX (1) MX2020004151A (enExample)
SG (1) SG11202003793WA (enExample)
WO (1) WO2019086463A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
EP4192806A1 (en) 2020-08-05 2023-06-14 Takeda Pharmaceutical Company Limited Methods for preparing and purifying environmentally compatible detergents
WO2024115344A1 (en) 2022-11-29 2024-06-06 Merck Patent Gmbh Method for inactivating enveloped viruses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009537508A (ja) 2006-05-19 2009-10-29 ビロブロック エスアー エンベロープウイルスを不活化させるための組成物
US20150094240A1 (en) 2013-09-30 2015-04-02 Resman As Chemical compounds
US20160186094A1 (en) 2013-04-09 2016-06-30 Materia, Inc. Preparation of surfactants via cross-metathesis

Family Cites Families (378)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1970578A (en) 1930-11-29 1934-08-21 Ig Farbenindustrie Ag Assistants for the textile and related industries
GB1041554A (en) 1961-10-11 1966-09-07 W J Bush & Company Ltd Improvements in or relating to the dyeing of fibres
DE2154996A1 (de) 1971-11-05 1973-05-10 Bayer Ag Anthrachinonfarbstoffe
JPS527372B2 (enExample) 1972-07-14 1977-03-02
US4020183A (en) 1974-12-03 1977-04-26 Ortho Pharmaceutical Corporation Nonionic surface active anti-herpes simplex viral agents
SE437329B (sv) 1975-03-14 1985-02-25 Community Blood Council Sett att ur blodserum framstella vaccin mot virushepatit
JPS5265591A (en) 1975-11-26 1977-05-31 Mitsui Petrochem Ind Ltd Purification of polyolefins
DE2605469C3 (de) 1976-02-12 1980-04-10 Behringwerke Ag, 3550 Marburg Verfahren zur Gewinnung eines Spaltprodukts des Tollwut-Virus und dieses enthaltender Impfstoff
US4113712A (en) 1976-03-08 1978-09-12 The Green Cross Corporation HBsAG Particle composed of single polypeptide subunits and the preparation procedure
DE2615161A1 (de) 1976-04-07 1977-10-27 Thiemann Chem Pharm Fab Omega-aminoalkoxy-alkane, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FI66020C (fi) 1977-09-19 1984-08-10 Merck & Co Inc Foerfarande foer framstaellning av antigeniska immunogeniska subunits av hsv-1 och hsv-2
US4374127A (en) 1977-09-19 1983-02-15 Merck & Co., Inc. Herpes sub unit vaccine
DE2750045A1 (de) 1977-11-09 1979-05-10 Behringwerke Ag Verfahren zur entfernung von detergentien aus virusantigensuspensionen
ZA792485B (en) 1978-06-07 1980-06-25 New York Blood Center Inc Vaccine for active immunization containing hepatitis b surface and/or e-antigens
DE2847959A1 (de) 1978-11-04 1980-05-14 Behringwerke Ag Verfahren zur isolierung von virusantigenen mittels polyaethylenglykol aus loesungen, die nicht-ionische detergentien enthalten
JPS5940174B2 (ja) 1978-11-16 1984-09-28 財団法人相模中央化学研究所 液体シンチレ−タ−溶液
DK276380A (da) 1979-07-09 1981-01-10 Univ Iowa State Res Found Inc Fremgangsmaade til fremstilling af en vaccine mod infektioes kvaeg-rhinotracheitis
US4452734A (en) 1980-02-11 1984-06-05 Merck & Co., Inc. Herpes subunit vaccine
FR2475572A1 (fr) 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
DE3005495C2 (de) 1980-02-14 1983-03-31 Institut Pasteur, 75724 Paris Herstellung von Fragmenten von Viren mit Lipidhülle und sie enthaltende Arzneimittelzubereitungen
DE3014189A1 (de) 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
ZW9881A1 (en) 1980-06-02 1981-12-23 Hoffmann La Roche Substituted phenoxyaminopropanol derivatives
DE3173208D1 (en) 1980-10-06 1986-01-23 Edward Shanbrom Method of reducing undesirable activities of biological and pharmaceutical products
AR228580A1 (es) 1980-11-25 1983-03-30 Torre Jose Leonardo Procedimiento para inactivar el virus de la fiebre aftosa
JPS5795917A (en) 1980-12-04 1982-06-15 Takeda Chem Ind Ltd Preparation of inactivated sendai virus vaccine
US4327182A (en) 1981-01-22 1982-04-27 Connaught Laboratories Incorporated Purification of influenza sub-unit vaccine
US4975217A (en) 1981-07-20 1990-12-04 Kimberly-Clark Corporation Virucidal composition, the method of use and the product therefor
US4481189A (en) 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4645666A (en) 1982-06-08 1987-02-24 The Regents Of The University Of California Vaccine for bluetongue disease employing platinum compounds
US4511556A (en) 1982-06-10 1985-04-16 The United States Of America As Represented By The Department Of Health And Human Services Inactivation of a lipid virus
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
JPS6041770A (ja) 1983-08-17 1985-03-05 Hitachi Ltd 燃料電池装置
JPS6051120A (ja) 1983-08-31 1985-03-22 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニットワクチン
GB8405521D0 (en) 1984-03-02 1984-04-04 Abm Chemicals Ltd End-blocked nonionic surfactants
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4613501A (en) 1984-12-21 1986-09-23 New York Blood Center, Inc. Inactivation of viruses in labile blood derivatives
US4673733A (en) 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
AT385203B (de) 1985-04-26 1988-03-10 Immuno Ag Verfahren zur herstellung einer fruehsommermeningoenzephalitis-virus (fsme-virus)-vakzine
US4649192A (en) 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
EP0232410A4 (en) 1985-08-15 1988-01-25 Amgen CLEAVAGE PROCESS AND BUFFER FOR THE EXTRACTION OF HEPATITIS B SURFACE ANTIGENS FROM YEAR CELLS.
US5426029A (en) 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
US4789545A (en) 1986-03-31 1988-12-06 New York Blood Center, Inc. Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof
DE3704550A1 (de) 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US4943624A (en) 1988-10-28 1990-07-24 Lehigh University Supramolecular surfactants: amphiphilic polymers designed to disrupt lipid membranes
JPH02184842A (ja) 1989-01-11 1990-07-19 Konica Corp 帯電防止性及び塗布性が改良されたハロゲン化銀写真感光材料
CA2007545A1 (en) 1989-01-13 1990-07-13 Yahiro Uemura Production method for protein-containing composition
HK1003981A1 (en) 1989-01-27 1998-11-13 Immunolytics, Inc. Composition and method for treating benign prostatic hypertrophy
JPH02272068A (ja) 1989-04-13 1990-11-06 Mitsubishi Monsanto Chem Co 合わせガラス用着色ポリビニルブチラール中間膜及びその着色剤組成物
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
AU636907B2 (en) 1989-08-29 1993-05-13 Commonwealth Scientific And Industrial Research Organisation Bovine ephemeral fever and antigens and vaccines derived therefrom
GB8919819D0 (en) 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
JPH03168737A (ja) 1989-11-29 1991-07-22 Konica Corp 高コントラストな画像と高品質な網点が得られるハロゲン化銀写真感光材料
US5418130A (en) 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US6251644B1 (en) 1990-04-16 2001-06-26 Baxter International, Inc. Method for inactivating non-enveloped viral contaminants with a photosensitizer by increasing viral permeability to the photosensitizer
US5712086A (en) 1990-05-15 1998-01-27 New York Blood Center, Inc. Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactions
US5232844A (en) 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5981163A (en) 1990-05-15 1999-11-09 New York Blood Center, Inc. Process for the sterilization of biological compositions using irradiation and quenchers of type I and type II photodynamic reactions
DE4033446A1 (de) 1990-10-20 1992-04-23 Bayer Ag Impfstoffe gegen equine herpesviren und ihre herstellung
US5314917A (en) 1991-03-22 1994-05-24 E. B. Michaels Research Associates, Inc. Method for inactivating enveloped viruses and sperm
IT1248075B (it) 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
DE4125625C2 (de) 1991-08-02 1999-12-02 Octapharma Ag Glarus Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
AU657168B2 (en) 1991-09-18 1995-03-02 Amgen, Inc. Hepatitis B vaccine with bile salt adjuvant
FR2686221B1 (fr) 1992-01-22 2000-02-25 Hutchinson Compositions a base d'antiseptiques et leurs applications.
WO1993017723A1 (en) 1992-03-02 1993-09-16 Simmons Paul L Biodegradable surface disinfectant
AU667530B2 (en) 1992-05-28 1996-03-28 New York Blood Center, Inc., The Removal of antibodies from blood-derived compositions while retaining coagulation factors
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
AU6653094A (en) 1992-12-16 1994-07-04 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
FI953756L (fi) 1993-02-09 1995-09-12 Octapharma Ag Menetelmä lipidivaipattomien virusten inaktivoimiseksi
SE9301582D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Purification of plasma proteins
AU696246B2 (en) 1993-05-28 1998-09-03 New York Blood Center, Inc., The Process for the sterilization of biological compositions and the product produced thereby
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
DE4342132C1 (de) 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
US5486293A (en) 1994-03-21 1996-01-23 Hemasure, Inc. Removal of small exogenous molecules from biological fluids
US5514781A (en) 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
US5627080A (en) 1994-07-29 1997-05-06 Beckman Instruments, Inc. Detergent-facilitated immunoassay for the rapid and quantitative assay of pharmacological agents
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
WO1996028025A1 (en) 1995-03-10 1996-09-19 Hemasure, Inc. Inactivation of pathogens in blood and/or blood products using formaldehyde
US5985275A (en) 1995-04-12 1999-11-16 New York Blood Center β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
US6034073A (en) 1995-04-24 2000-03-07 Novavax, Inc. Solvent detergent emulsions having antiviral activity
FI952196A0 (fi) 1995-05-08 1995-05-08 Suomen Punainen Risti Veripalv Framstaellning av immunoglobulin
US6136865A (en) 1995-05-20 2000-10-24 Octapharma Ag Method for reduction of the infectiousness of potentially infectious material
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
DE19528221C2 (de) 1995-08-01 1998-10-22 Blutspendedienst Der Drk Lande Verfahren zur Herstellung eines virussicheren, therapeutischen Präparates aus Humanplasma
DE19544297A1 (de) 1995-11-28 1997-06-05 Behringwerke Ag Verfahren zur Entfernung von aromatischen Verbindungen aus produkthaltigen Lösungen
ES2099678B1 (es) 1995-11-03 1998-02-16 Grifols Grupo Sa Procedimiento para la inactivacion de virus en proteinas.
US5952009A (en) 1996-03-20 1999-09-14 New York Blood Center Methods for preventing the transmission of or treating patients infected with herpesvirus
US5700679A (en) 1996-06-07 1997-12-23 Novavax, Inc. Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity
DE19633684A1 (de) 1996-08-12 1998-02-19 Dirk Dipl Ing Vollenbroich Verfahren zur Inaktivierung von lipidumhüllten Viren
US6440980B1 (en) 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US20060275781A1 (en) 2004-11-03 2006-12-07 Introgen Therapeutics Inc. Novel method for the protection and purification of adenoviral vectors
EP1364944A1 (en) 1997-01-06 2003-11-26 Cerus Corporation Frangible Compounds for Pathogen Inactivation
AT405939B (de) 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
AU6959998A (en) 1997-04-10 1998-10-30 Life Technologies, Inc. Rna isolation reagent and methods
KR20010013377A (ko) 1997-06-04 2001-02-26 데이비드 엠 모이어 마일드한 잔류성 항균 조성물
KR100661760B1 (ko) 1997-08-04 2006-12-28 가부시끼가이샤 센탈 세메 가가꾸 겐꾸쇼 바이러스 검출 또는 검정 방법
US6162904A (en) 1997-12-24 2000-12-19 Alpha Therapeutic Corporation Manufacturing method for intraveneously administrable immune globulin and resultant product
US6165458A (en) 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
SI1150712T1 (sl) 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
WO2000061613A2 (en) 1999-04-09 2000-10-19 The Johns Hopkins University Channel forming toxins as antiviral agents
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7087399B1 (en) 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
US7273567B1 (en) 1999-11-24 2007-09-25 Microactive Corp. Energy-activated compositions for controlled sustained release of a gas
US6441144B1 (en) 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
US7279318B1 (en) 1999-06-09 2007-10-09 Hybrid Systems Limited Modification of biological elements
CZ20014456A3 (cs) 1999-06-15 2002-05-15 Alpha Therapeutic Corporation Způsob přípravy intravenózního immunoglobulinu a přípravku, který jej obsahuje
US6861397B2 (en) 1999-06-23 2005-03-01 The Dial Corporation Compositions having enhanced deposition of a topically active compound on a surface
SE9902388D0 (sv) 1999-06-23 1999-06-23 Pharmacia & Upjohn Ab Method for purification of proteins
AU5471000A (en) 1999-06-23 2001-01-09 Dial Corporation, The Antibacterial compositions
MXPA01013312A (es) 1999-06-23 2003-09-04 Dial Corp Composiciones antibacterianas.
AU7097400A (en) 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20050232868A1 (en) 1999-10-19 2005-10-20 The Procter & Gamble Company Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
US6517849B1 (en) 1999-10-19 2003-02-11 The Procter & Gamble Company Tissue products containing antiviral agents which are mild to the skin
US6462180B1 (en) 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
CN1286969C (zh) 1999-12-14 2006-11-29 热生物之星公司 多肽和抗原的稳定稀释剂
EP1241940B1 (en) 1999-12-30 2004-08-25 Kimberly-Clark Worldwide, Inc. Antimicrobial absorbent article, and methods of making and using the same
US6893462B2 (en) 2000-01-11 2005-05-17 Regeneration Technologies, Inc. Soft and calcified tissue implants
US20020172656A1 (en) 2000-01-20 2002-11-21 Biedermann Kimberly Ann Cleansing compositions
BR0107748A (pt) 2000-01-20 2002-10-22 Procter & Gamble Composições antimicrobianas
CA2799545A1 (en) 2000-03-07 2001-09-13 Merck Sharp & Dohme Corp. Adenovirus formulations
CN100489107C (zh) 2000-04-28 2009-05-20 圣朱德儿童研究医院 用于产生感染性流感病毒的dna转染系统
IL136552A (en) 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
AUPQ846900A0 (en) 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US20020018792A1 (en) 2000-06-30 2002-02-14 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care anti-sebum compositions containing 3,4,4-trichlorocarbanilide
JP2002085057A (ja) 2000-09-12 2002-03-26 Yoshiaki Nagaura ウィルスを不活化する方法
AU2001292917A1 (en) 2000-09-20 2002-04-02 Regeneration Technologies, Inc. Method of preparing and processing transplant tissue
NZ525076A (en) 2000-10-02 2004-09-24 Glaxosmithkline Biolog S A split enveloped RSV virus vaccine fomulation
ES2543829T5 (es) 2000-12-14 2023-07-13 Grifols Therapeutics Inc Procedimiento para la preparación del inhibidor de proteinasa alfa 1
US20040071734A1 (en) 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
CN1230526C (zh) 2001-02-27 2005-12-07 成都夸常科技有限公司 一种除去作为病毒灭活剂的有机溶剂和/或去污剂的方法
EP1370643A1 (en) 2001-03-16 2003-12-17 Oncolytics Biotech, Inc. Method of extracting virus from cell culture
US6803041B2 (en) 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
US6635679B2 (en) 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
EP2545937A1 (en) 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
AU2002322284A1 (en) 2001-06-25 2003-01-08 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
FR2827610B1 (fr) * 2001-07-17 2005-09-02 Commissariat Energie Atomique Composition de degraissage utilisable pour le degraissage et/ou la decontamination de surfaces solides
CN1208091C (zh) 2001-08-30 2005-06-29 成都夸常科技有限公司 用固定化溶剂或固定化溶剂－去污剂灭活病毒的方法
US20060110407A1 (en) 2001-12-05 2006-05-25 Shelley Stopera Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
US20030133829A1 (en) 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
GB0201039D0 (en) 2002-01-17 2002-03-06 Incenta Ltd Assay
BR0306925A (pt) 2002-01-18 2004-11-09 Schering Ag Formulações estabilizadas de adenovìrus
US20040142450A1 (en) 2002-05-10 2004-07-22 Seo Sang Heui Lung epithelial cell line for propagating viruses
ES2285120T3 (es) 2002-05-14 2007-11-16 MERCK & CO., INC. Procedimientos de purificacion de adenovirus.
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
AR040819A1 (es) 2002-08-08 2005-04-20 Alza Corp Dispositivo de administracion transdermica de vacuna que tiene microproyecciones revestidas
WO2004015004A2 (en) 2002-08-09 2004-02-19 General Motors Corporation Gel coat composition
CA2496918A1 (en) 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
CA2500661A1 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
SE0203551D0 (sv) 2002-12-02 2002-12-02 Biovitrum Ab Prothrombin purification
NZ543467A (en) 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
AU2004249133B2 (en) 2003-05-28 2009-05-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
EP1633322A2 (en) 2003-06-04 2006-03-15 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
MXPA05013389A (es) 2003-06-25 2006-03-17 Pharmexa As Purificacion de variantes her-2.
KR20060033870A (ko) 2003-06-25 2006-04-20 파멕사 에이/에스 Ｈｅｒ-2 변이체의 정제
HRP20080235T3 (hr) 2003-07-24 2008-07-31 Merial Limited Formulacija vakcine koja sadrži emulziju ulje-u-vodi
JP5189765B2 (ja) 2003-08-01 2013-04-24 バイオコン・リミテッド 加水分解可能なプロドラッグのためのアリールカルバメートオリゴマーおよびこれを含むプロドラッグ
WO2005014648A1 (en) 2003-08-12 2005-02-17 Octapharma Ag Process for preparing an alpha-1-antitrypsin solution
US7037707B2 (en) 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
EP1691198B1 (en) 2003-10-28 2010-10-20 Advanced Life Science Institute, Inc. Method of detecting hepatitis c virus
WO2005049077A2 (en) 2003-11-17 2005-06-02 Regents Of The University Of Minnesota Avian vaccine effective against infectious bursal disease virus
EP1711513B1 (en) 2003-12-01 2014-07-02 Novo Nordisk Health Care AG Nanofiltration of factor vii solutions to remove virus
BRPI0417938A (pt) 2003-12-30 2007-04-17 Wyeth Corp formulações de proteìnas hidrofóbicas em uma composição imunogênica que possui tolerabilidade aperfeiçoada
EP1709162A2 (en) 2004-01-27 2006-10-11 Bharat Biotech International Limited A novel process of hepatitis a vaccine preparation
CN1922308A (zh) 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
WO2009131606A2 (en) 2008-02-01 2009-10-29 Belanger Julie M Viral inactivation using crosslinkers and detergents
US8613934B2 (en) 2004-03-22 2013-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cellular and viral inactivation
US20050271711A1 (en) 2004-04-26 2005-12-08 The Procter & Gamble Company Therapeutic antimicrobial compositions and methods
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
JP5112060B2 (ja) 2004-06-29 2013-01-09 リライアンス ライフ サイエンシーズ プライベイト リミテッド ウイルス安全性生物学的流体の調製のための方法
WO2006003926A1 (ja) 2004-06-30 2006-01-12 Terumo Kabushiki Kaisha ウィルス不活化ヘモグロビンおよびその製造方法
PL2236155T3 (pl) 2004-09-09 2012-10-31 Novartis Ag Zmniejszenie potencjalnego zagrożenia jatrogennego związanego ze szczepionkami przeciwko grypie
EP2923711A1 (en) 2004-11-03 2015-09-30 Novartis Vaccines and Diagnostics, Inc. Influenza vaccination
AU2005229674B2 (en) 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
EP1827099A2 (en) 2004-12-09 2007-09-05 The DIal Corporation Compositions having a high antiviral and antibacterial efficacy
MX2007006862A (es) 2004-12-09 2008-02-15 Dial Corp Composiciones que tienen alta eficacia antiviral y antibacterial.
EP1685852A1 (en) 2005-02-01 2006-08-02 Fondation pour la Recherche Diagnostique Set of disposable bags for viral inactivation of biological fluids
WO2006096461A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
TW200700079A (en) 2005-03-23 2007-01-01 Glaxosmithkline Biolog Sa Composition
US20070037192A1 (en) 2005-07-25 2007-02-15 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP1951200A2 (en) 2005-08-09 2008-08-06 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
WO2007022718A1 (fr) 2005-08-25 2007-03-01 Chunde Liu Alcools alkylaryle, leurs derives et leur procede de preparation
ES2359214T5 (es) 2005-11-01 2014-10-08 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual por tratamiento con beta-propiolactona
WO2007052059A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Changing th1/th2 balance in split influenza vaccines with adjuvants
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
US20100158943A1 (en) 2005-11-04 2010-06-24 Novartis Vaccines And Diagnostics Srl Administration routes for priming/boosting with influenza vaccines
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
CN101346152A (zh) 2005-11-04 2009-01-14 诺华疫苗和诊断有限公司 用细胞培养物培养的流感病毒制备含非病毒颗粒抗原的佐剂疫苗
KR101211386B1 (ko) 2005-11-04 2012-12-13 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 알루미늄 보조제에 즉석 흡착되는 인플루엔자 백신
PL1951299T3 (pl) 2005-11-04 2012-07-31 Novartis Ag Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność
US20070128693A1 (en) 2005-12-06 2007-06-07 Advantek Serum Laboratories Limited3/F Method for the inactivation and removal of dengue virus from biological samples
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
AU2006330922B2 (en) 2005-12-20 2012-07-26 Bristol-Myers Squibb Company Compositions and methods for producing a composition
KR20080089663A (ko) 2006-01-27 2008-10-07 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
US7794755B2 (en) 2006-04-11 2010-09-14 E.I. Du Pont De Nemours And Company Process for preparation of swellable and deformable microspheres
US8252339B2 (en) 2006-04-11 2012-08-28 Massachusetts Institute Of Technology Medical treatment applications of swellable and deformable microspheres
WO2007144772A2 (en) 2006-06-15 2007-12-21 Novartis Ag Adjuvant-sparing multi-dose influenza vaccination regimen
US20080003575A1 (en) 2006-06-28 2008-01-03 Sigma-Aldrich Co. Methods and composition for RNA extraction
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
EP2052340A4 (en) 2006-08-14 2010-11-17 Massachusetts Inst Technology SYSTEM FOR EXPLORING DATA ON GLYCANES
CN101501696A (zh) 2006-08-14 2009-08-05 麻省理工学院 聚糖数据挖掘系统
US20090081193A1 (en) 2006-08-14 2009-03-26 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
WO2008032219A2 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
US20090035339A1 (en) 2006-10-10 2009-02-05 Rudyard Istvan Methods of Inactivating Viruses
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
EP2091561A2 (en) 2006-12-15 2009-08-26 Schering-Plough Ltd. Method for replicating influenza virus in culture
WO2008096093A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses
GB0702416D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702385D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
JP4829828B2 (ja) 2007-03-28 2011-12-07 シスメックス株式会社 血液凝固測定用試薬及び組織因子安定化方法
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
US8747872B2 (en) 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US8288111B2 (en) 2007-05-24 2012-10-16 Abbott Laboratories Immunoassays exhibiting reduced cross-reactivity with hydrophobic drug analyte metabolites
US7557072B2 (en) 2007-06-12 2009-07-07 Rhodia Inc. Detergent composition with hydrophilizing soil-release agent and methods for using same
HRP20120790T1 (hr) 2007-06-27 2013-01-31 Novartis Ag Cjepiva protiv influence sa niskom koliäśinom aditiva
US8497112B2 (en) 2007-08-28 2013-07-30 Baxter International Inc. Method for producing viral vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
WO2009081172A1 (en) 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
CA2711330A1 (en) 2008-01-03 2009-07-16 Massachusetts Institute Of Technology Decoy influenza therapies
WO2009089121A2 (en) 2008-01-03 2009-07-16 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
EP2077118A1 (en) 2008-01-07 2009-07-08 Gwo Rei Biomedical Technology Corp. Clottable concentrate of platelet growth factors and preparation method thereof
ES2535101T3 (es) 2008-03-18 2015-05-05 Novartis Ag Mejoras en la preparación de antígenos en vacuna de virus de la gripe
US20110009520A1 (en) 2008-03-20 2011-01-13 Figuly Garret D Dimensionally stable, shaped articles comprised of dried, aggregated, water-swellable hydrogel microspheres and method of making same
EP2278997B1 (en) 2008-04-21 2016-08-10 Nanobio Corporation Nanoemulsion influenza vaccine
EP2274320A1 (en) 2008-04-25 2011-01-19 ID Biomedical Corporation of Quebec Methods for preparing immunogenic compositions
GB0905570D0 (en) 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
EP2300497B1 (en) 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii
US20110237781A1 (en) 2008-07-18 2011-09-29 Talecris Biotherapeutics, Inc. Method of preparing alpha-1 proteinase inhibitor
JP5722782B2 (ja) 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
TWI610936B (zh) 2008-10-20 2018-01-11 艾伯維有限公司 使用蛋白質ａ親和性層析進行抗體之分離及純化
US8647835B2 (en) 2008-10-31 2014-02-11 BIO MéRIEUX, INC. Methods for separation, characterization and/or identification of microorganisms using spectroscopy
EP2364356B1 (en) 2008-10-31 2019-06-19 Biomerieux, Inc Methods for detection and identification of microorganisms
EP2352992B1 (en) 2008-10-31 2020-04-22 bioMerieux, Inc. Methods for identification of microorganisms using spectroscopy
BRPI0919896A2 (pt) 2008-10-31 2016-02-16 Bio Merieux Inc metodos para a separacao,caracterizacao e/ou identificacao de micro-organismos por espectroscopia de massa.
CN102272585B (zh) 2008-10-31 2015-10-07 生物梅里埃公司 采用拉曼光谱法分离、表征和/或鉴定微生物的方法
EP2364447B1 (en) 2008-10-31 2019-06-12 Biomerieux, Inc Method for the identification of microorganisms
JP2012507272A (ja) 2008-11-05 2012-03-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
CA2742817A1 (en) 2008-11-20 2010-05-27 Biogen Idec Ma Inc. Arginine inactivation of viruses
WO2010092477A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
EP2396032B1 (en) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
CA2754826A1 (en) 2009-03-06 2010-09-10 Mount Sinai School Of Medicine Live attenuated influenza virus vaccines comprising microrna response elements
CA2763816A1 (en) 2009-04-27 2010-11-04 Novartis Ag Adjuvanted vaccines for protecting against influenza
NZ596296A (en) 2009-05-08 2013-08-30 Novartis Ag Generic assays for detection of influenza viruses
KR20120026526A (ko) 2009-05-12 2012-03-19 트랜스진 에스.에이. 불멸화 조류 세포주 및 그의 용도
EP2401384B1 (en) 2009-05-21 2012-10-03 Novartis AG Reverse genetics using non-endogenous pol i promoters
BRPI1012082B1 (pt) 2009-05-27 2022-08-16 Takeda Pharmaceutical Company Limited Método para preparar uma composição de igg concentrada a partir de plasma
JP5823379B2 (ja) 2009-05-29 2015-11-25 ノバルティス アーゲー インフルエンザウイルスヘマグルチニンについてのアッセイ
BRPI1014031A2 (pt) 2009-06-16 2018-02-20 Univ Michigan Regents vacinas de nanoemulsão
WO2011003100A2 (en) 2009-07-02 2011-01-06 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
AT516600B1 (de) 2009-07-23 2016-07-15 Baxter Int Herstellung von faktor h (fh) und fh-derivaten aus plasma
CN102666860B (zh) 2009-07-31 2015-06-17 诺华股份有限公司 反向遗传系统
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
CA2773637A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
US9107859B2 (en) 2009-09-10 2015-08-18 Merial, Inc. Vaccine formulations comprising saponin-containing adjuvants
SI2491117T1 (sl) 2009-10-20 2014-03-31 Novartis Ag Izboljšani postopki reverzne genetike za pridobivanje virusov
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
US20120240937A1 (en) 2009-12-09 2012-09-27 Glaxosmithkline Llc Coating for Latex Articles
IT1397061B1 (it) 2009-12-28 2012-12-28 Kedrion Spa Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale.
CN101732711A (zh) 2009-12-31 2010-06-16 中国人民解放军军事医学科学院微生物流行病研究所 一种喷鼻免疫流感五价或多价灭活疫苗的制备及其应用
US9701723B2 (en) 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
RU2590726C2 (ru) 2010-03-30 2016-07-10 Октафарма Аг Способ очистки витамин к-зависимых белков, таких как коагуляционный фактор ix
DK2552948T3 (en) 2010-03-30 2016-10-17 Octapharma Ag A process for the purification of the protein growth factor G-CSF
CA2797059A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
BR112012028146A2 (pt) 2010-05-06 2015-09-15 Novartis Ag compostos de peróxido orgânico para inativação de microorganismos
JP5876036B2 (ja) 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
EP2389942B1 (en) 2010-05-25 2013-01-23 GwoWei Technology Co., Ltd. Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US20130243841A1 (en) 2010-06-01 2013-09-19 Novartis Ag Concentration of vaccine antigens with lyophilization
DK2575872T3 (da) 2010-06-01 2020-10-19 Seqirus Uk Ltd Koncentrering af influenzavaccineantigener uden frysetørring
CN103119058A (zh) 2010-07-23 2013-05-22 巴克斯特国际公司 由血浆生产间-α-抑制蛋白(IAIP)
EP3012330A1 (en) 2010-09-07 2016-04-27 Novartis AG Generic assays for detection of mammalian reovirus
EP2640405A4 (en) 2010-09-21 2015-04-15 Massachusetts Inst Technology HA-POLYPEPTIDES ADAPTED TO HUMANS, VACCINES THEREOF AND INFLUENZA TREATMENT THEREWITH
SG10201709806VA (en) 2010-10-04 2017-12-28 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
BR112013010338A2 (pt) 2010-10-27 2016-08-02 Glaxosmithkline Biolog Sa composição, métodos para preparar uma composição imunogênica, para adjuvantar uma resposta imune, para eliciar uma resposta imune contra um agente infeccioso, para evitar e/ou reduzir a deposição de amilóide ou doença de alzheimer em um indivíduo, e para tratar/reduzir/melhorar a infecção por uma agente infeccioso, uso de uma proteína, e, kit
WO2012061239A2 (en) 2010-11-02 2012-05-10 Opko Pharmaceuticals, Llc Novel vaccines against pandemic influenza virus a/h1n1
BR112013010830A2 (pt) 2010-11-02 2017-12-12 Hector Manuel Zepeda Lopez vacina inovadoras contra o vírus da influenza pandêmica a/h1n1
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
CN102464974B (zh) 2010-11-17 2013-08-07 中国石油化工股份有限公司 可大幅度提高原油采收率的组合物及其制备方法
US20120208982A1 (en) * 2010-12-15 2012-08-16 Baxter Healthcare S.A. Viral Inactivation Using Improved Solvent-Detergent Method
IL210162A0 (en) 2010-12-21 2011-03-31 Omrix Biopharmaceuticals Viral inactivated platelet extract, use and preparation thereof
WO2012118789A2 (en) 2011-02-28 2012-09-07 The Ohio State University Enhanced removal of viruses from fresh produce
KR20120098202A (ko) 2011-02-28 2012-09-05 (주)차바이오앤디오스텍 자하거 추출물 및 자하거 추출물 제조 방법
ES2641618T3 (es) 2011-03-04 2017-11-10 Baxalta GmbH Método para la determinación de polisorbato
US9017950B2 (en) 2011-03-18 2015-04-28 Luminescent MD, LLC Method for enhancing enzyme assays
TR201810703T4 (tr) 2011-03-25 2018-08-27 Hoffmann La Roche Yeni protein saflaştırma yöntemleri.
PH12013502442A1 (en) 2011-05-26 2018-03-21 Glaxo Smithkline Biologicals Sa Inactivated dengue virus vaccine
AU2012279154A1 (en) 2011-07-01 2014-02-20 The Regents Of The University Of California Herpes virus vaccine and methods of use
WO2013006797A1 (en) 2011-07-06 2013-01-10 Nanobio Corporation Human respiratory syncytial virus vaccine
EP2734280A4 (en) 2011-07-22 2015-04-15 Bio Merieux Inc METHOD AND NECESSARY INSULATING MICROORGANISMS OF A CULTURE
HUE035941T2 (en) 2011-08-02 2018-05-28 Baxalta GmbH Systems and Methods for Recombinant Production Methods to Increase Protein Yield
CN104093421A (zh) 2011-09-09 2014-10-08 纳诺碧欧公司 纳米乳液呼吸道合胞病毒(rsv)亚单位疫苗
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
EP2768528A1 (en) 2011-10-20 2014-08-27 Novartis AG Adjuvanted influenza b virus vaccines for pediatric priming
WO2013135274A1 (en) 2012-03-13 2013-09-19 Intercell Ag Aluminium compounds for use in therapeutics and vaccines
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
ES2628301T3 (es) 2012-03-02 2017-08-02 Seqirus UK Limited Recombinación de virus de gripe
GB201205189D0 (en) 2012-03-23 2012-05-09 Glaxosmithkline Biolog Sa Novel medical use
US20130315955A1 (en) 2012-04-13 2013-11-28 Protein Sciences Corporation Stability and potency of hemagglutinin
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
CN102614508B (zh) 2012-04-28 2013-10-30 长春生物制品研究所有限责任公司 一种人用流感病毒裂解疫苗的病毒裂解灭活方法
SG11201406407TA (en) 2012-06-29 2014-11-27 Emd Millipore Corp Methods for inactivating viruses during a protein purification process
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
US9353165B2 (en) 2012-07-25 2016-05-31 Grifols, S.A. Purification of cell culture derived alpha1 protease inhibitor
EP2879691B1 (en) 2012-08-06 2019-03-27 Biogen MA Inc. Methods for inactivating enveloped viruses
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
RU2015121410A (ru) 2012-11-05 2016-12-27 МЕДИММЬЮН, ЭлЭлСи Способ выделения synagis® в условиях отсутствия бензоназы
AU2013354219A1 (en) 2012-12-03 2015-07-02 Novartis Ag Reassortant influenza a viren
CN102943000A (zh) 2012-12-17 2013-02-27 江南大学 一种活性氧增彩洗衣液
CN109045294A (zh) 2013-01-10 2018-12-21 思齐乐 流感病毒免疫原性组合物及其应用
MX2015009330A (es) 2013-01-23 2016-04-15 Novartis Ag Reordenamiento del virus de influenza.
TWI641382B (zh) 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
EP2953967B1 (en) 2013-02-07 2019-05-01 Massachusetts Institute of Technology Human adaptation of h5 influenza
US9393252B2 (en) 2013-03-12 2016-07-19 Ecolab Usa Inc. Aromatic carboxylic acids in combination with aromatic hydroxyamides for inactivating non-enveloped viruses
HK1218511A1 (zh) 2013-03-13 2017-02-24 Novartis Ag 乙型流感病毒重配
WO2014167582A2 (en) 2013-03-31 2014-10-16 Ella Foundation Vaccine composition for prophylaxis in ruminants
WO2015126462A1 (en) 2014-02-19 2015-08-27 Materia, Inc. Preparation of surfactants via cross-metathesis
WO2014179464A1 (en) 2013-04-30 2014-11-06 Massachusetts Institute Of Technology Human adaptation of h3 influenza
FR3005265B3 (fr) 2013-05-06 2017-01-27 Novartis Ag Reassortiment du virus de la grippe
JP2016521282A (ja) 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
WO2014197723A2 (en) 2013-06-05 2014-12-11 Massachusetts Institute Of Technology Human adaptation of h7 ha
JP2016521553A (ja) 2013-06-06 2016-07-25 ノバルティス アーゲー インフルエンザウイルス再集合
EP3043813B1 (en) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
CN103392691B (zh) 2013-08-14 2015-09-23 北京瑞健高科生物科技有限公司 一种生物组织处理、灭菌及保存的容器和方法
WO2015031689A1 (en) 2013-08-30 2015-03-05 Personalis, Inc. Methods and systems for genomic analysis
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
PT3060229T (pt) 2013-10-24 2021-10-07 Astrazeneca Ab Formulações aquosas estáveis de anticorpos
CA2930687C (en) 2013-11-15 2024-04-23 Genentech, Inc. Methods for viral inactivation using eco-friendly detergents
US20160287693A1 (en) 2013-11-15 2016-10-06 Novartis Ag Removal of residual cell culture impurities
US20160304586A1 (en) 2013-12-05 2016-10-20 Crucell Holland B.V. Process for preparing influenza vaccines
WO2015100344A1 (en) 2013-12-27 2015-07-02 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
TWI671312B (zh) 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
CA3206112A1 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015158776A1 (en) 2014-04-15 2015-10-22 Boehringer Ingelheim International Gmbh Methods, apparatuses, and systems for continuously inactivating a virus during manufacture of a biological product
KR20170035891A (ko) 2014-06-13 2017-03-31 산타 마리아 바이오테라퓨틱스, 인코포레이티드 제형화된 수용체 폴리펩타이드 및 관련 방법
WO2016028776A1 (en) 2014-08-18 2016-02-25 Sanofi Pasteur Biologics Llc Alkylated influenza vaccines
CN104211943B (zh) 2014-09-17 2016-08-24 南京卡邦科技有限公司 一种制备分离单分散聚乙二醇的方法
CN104324370B (zh) 2014-09-30 2019-12-20 普莱柯生物工程股份有限公司 疫苗组合物及其制备方法和应用
WO2016063299A2 (en) 2014-10-21 2016-04-28 Gennova Biopharmaceuticals Limited A novel purification process for isolation and commercial production of recombinant tnk-tpa (tenecteplase)
MD3227325T2 (ro) 2014-12-01 2024-09-30 Ferring Bv Compoziții de inhibitor selectiv trans-semnalizare de IL-6
MX2017007067A (es) 2014-12-01 2018-04-30 Ferring Bv Administracion de un inhibidor selectivo de la trans-señalizacion de il-6.
WO2016100926A1 (en) 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza
EP3233116A4 (en) 2014-12-19 2018-05-30 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
CN104548084A (zh) 2014-12-30 2015-04-29 吕宏亮 一种广谱粘膜免疫防控猪繁殖与呼吸综合症的疫苗组合物及其应用
CN107428817B (zh) 2015-03-12 2022-07-12 免疫医疗有限责任公司 纯化白蛋白融合蛋白的方法
PT3274447T (pt) 2015-03-27 2020-01-21 Cadila Healthcare Ltd Vacina baseada no vírus da papeira recombinante jeryl lynn 2
JP6651300B2 (ja) 2015-04-23 2020-02-19 山本化成株式会社 フタロシアニン化合物、これを含有する近赤外線カットフィルタ
AU2016270979B2 (en) 2015-06-02 2020-11-12 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
WO2016201127A1 (en) 2015-06-09 2016-12-15 Sanofi Pasteur, Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
WO2017004153A1 (en) 2015-06-29 2017-01-05 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
WO2017053374A1 (en) 2015-09-21 2017-03-30 Oregon Health & Science University Design and characterization of influenza vaccines
WO2017053413A1 (en) 2015-09-21 2017-03-30 Oregon Health & Science University Vaccines intelligently produced by epitope recombination (viper) for influenza
CN109311965B (zh) 2016-03-11 2023-07-18 勃林格殷格翰国际公司 在制造蛋白质期间连续灭活病毒的方法
CN106187713A (zh) 2016-07-19 2016-12-07 南通市晗泰化工有限公司 烷基苯甲醇聚氧乙烯醚羟丙基烯丙基醚及衍生物及其制备方法
CN106187828A (zh) 2016-07-19 2016-12-07 南通市晗泰化工有限公司 烷基苯甲醇聚氧乙烯醚琥珀酸二钠盐及其制备方法
CN106187714A (zh) 2016-07-19 2016-12-07 南通市晗泰化工有限公司 烷基苯甲醇聚氧乙烯醚及其制备方法
CN106187833A (zh) 2016-07-19 2016-12-07 南通市晗泰化工有限公司 烷基苯甲醇聚氧乙烯醚硫酸铵及其制备方法
CN106117264A (zh) 2016-07-19 2016-11-16 南京林业大学 烷基苯甲醇聚氧乙烯醚磷酸铵及其制备方法
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN109400449B (zh) 2018-09-29 2022-06-10 中国日用化学研究院有限公司 一种制备烷基苯基醇聚氧乙烯醚的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009537508A (ja) 2006-05-19 2009-10-29 ビロブロック エスアー エンベロープウイルスを不活化させるための組成物
US20160186094A1 (en) 2013-04-09 2016-06-30 Materia, Inc. Preparation of surfactants via cross-metathesis
US20150094240A1 (en) 2013-09-30 2015-04-02 Resman As Chemical compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANTILLO D. et al.，A Scalable Procedure for Light-Induced Benzylic Brominations in Continuous Flow，The Journal of Organic Chemistry，2013年11月21日，Vol.79，p.223-229
CONLEY L. et al.，Evaluation of Eco-Friendly Zwitterionic Detergents for Enveloped Virus Inactivation，BIOTECHNOLOGY and BIOENGINEERING，2016年11月09日，Vol.114, No.4，p.813-820
LI Y. et al.，Microcalorimetric Study on Micellization of Nonionic Surfactants with a Benzene Ring or Adamantane in Their Hydrophobic Chains，J. Phys. Chem. B，2005年，Vol.109，p.16070-16074
TILLER G. E. et al.，Hydrogenation of Triton X-100 Eliminates Its Fluorescence and Ultraviolet Light Absorption while Preserving Its Detergent Properties，ANALYTICAL BIOCHEMISTRY，1984年，Vol.141，p.262-266

Also Published As

Publication number Publication date
EP3704178B1 (en) 2024-07-24
RU2020117357A3 (enExample) 2022-03-30
CO2020006181A2 (es) 2020-10-30
US20210032567A1 (en) 2021-02-04
KR102651043B1 (ko) 2024-03-22
AU2018357917B2 (en) 2024-08-01
KR20200071127A (ko) 2020-06-18
BR112020008414A2 (pt) 2020-11-17
WO2019086463A1 (en) 2019-05-09
EP3704178A1 (en) 2020-09-09
AU2018357917A1 (en) 2020-05-07
US12258540B2 (en) 2025-03-25
SG11202003793WA (en) 2020-05-28
ES2991988T3 (es) 2024-12-05
CA3080656A1 (en) 2019-05-09
CN111511800B (zh) 2023-11-28
MX2020004151A (es) 2020-08-13
CN111511800A (zh) 2020-08-07
JP2021501163A (ja) 2021-01-14
RU2020117357A (ru) 2021-12-01

Similar Documents

Publication Publication Date Title
JP7432506B2 (ja) 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤
Ferguson et al. Hydrogen ion buffers for biological research
KR101385927B1 (ko) 정제된 소포성 구내염 바이러스를 세포 배양물로부터 단리하기 위한 정제 방법
AU2011343811B2 (en) Viral inactivation using improved solvent-detergent method
CN105012947A (zh) 狂犬病病毒的纯化方法
WO2021202440A1 (en) Aptamers against sars-cov-2, compositions comprising aptamers against sars-cov-2 and methods of using the same
JP2005514427A (ja) 殺ウイルス性消毒薬
Howell et al. Absence of the polar organizing protein PopZ results in reduced and asymmetric cell division in Agrobacterium tumefaciens
US20070049732A1 (en) Ultra-high yield intravenous immune globulin preparation
US20240010590A1 (en) Methods for preparing and purifying environmentally compatible detergents
RU2802513C2 (ru) Экологически приемлемые моющие средства для инактивации вирусов с липидной оболочкой
HK40036975A (en) Environmentally compatible detergents for inactivation of lipid-enveloped viruses
HK40036975B (en) Environmentally compatible detergents for inactivation of lipid-enveloped viruses
JP2021501163A5 (enExample)
HK40033347A (en) Environmentally compatible detergents for inactivation of lipid-enveloped viruses
HK40033347B (zh) 灭活脂包膜病毒的环境相容性去污剂
FI101399B (fi) Menetelmä lysotsyymidimeerien valmistamiseksi
Khodsiani et al. Evaluation of the antiviral potential of gemini surfactants against influenza virus H1N1
KR102544922B1 (ko) 폴록사머 조성물 및 이의 제조 및 사용 방법
BR112020008414B1 (pt) Compostos detergentes ambientalmente compatíveis, composição que os compreende, seus usos, métodos de síntese de compostos e de preparação de fármaco biofarmacêutico, e métodos para inativação de vírus
Cooper et al. 91. Antituberculous compounds. Part VI. p-(ω-Alkoxyalkoxy)-N-arylbenzamidines and analogues
Jung et al. Optimization of reovirus production from mouse L‐929 cells in suspension culture
JP2005524707A (ja) 核酸の修飾のための方法および組成物
Yan et al. P53 gene mutations in non-Hodgkin’s lymphoma
CN103012784B (zh) 一种聚季铵盐的制备方法、由该方法获得的产品及其应用

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240205

R150 Certificate of patent or registration of utility model

Ref document number: 7432506

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150